Antag Therapeutics appoints CEO amid obesity drug development

Antag Therapeutics, a biopharmaceutical company focusing on treatments for obesity, has appointed Joerg Moeller as chief executive officer. With over 30 years’ experience, Dr Moeller was formerly head of global R&D and a member of the executive team at Bayer AG's pharmaceutical division. Most recently, he was CEO and executive board member of BenevolentAI. His appointment follows Antag’s completion in 2024 of a €80 million Series A financing, and IND (investigational new drug) clearance by the US Food and Drug Administration to advance its lead candidate AT-7687 into Phase 1 clinical development in early 2025. Dr Moeller succeeds Antag's co-founder and former CEO Alexander Sparre-Ulrich who will become the company’s chief operating officer. Dr Moeller holds an MD from Ruhr University Bochum, Germany.

Antag announced the appointment on 8 January 2025.